BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|December 16, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016
- Volume 12
- Issue 1
AMRI Acquires Whitehouse Laboratories
Author(s)Pharmaceutical Technology Editors
AMRI adds analytical capabilities to its outsourcing services offerings with the acquisition of Whitehouse Labs.
Advertisement
Albany Molecular Research Inc. (AMRI) announced on Dec. 15, 2015, that it has acquired all the outstanding equity interests of Whitehouse Laboratories for $54 million in cash, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.
Whitehouse Labs, based in Lebanon, NJ, offers testing solutions for life sciences including materials and excipients, container qualification and container closure integrity testing, analytical chemistry, drug delivery systems and device qualification programs, packaging, distribution, and stability and storage programs.
In a statement announcing the acquisition, William S. Marth, AMRI's president and chief executive officer noted that Whitehouse Labs’ service offerings meet the needs of its customers and will augment the company’s discovery, development, and manufacturing services.
Source:
Articles in this issue
almost 11 years ago
CMO Consolidation Pace May Slow Downalmost 11 years ago
Branded and Generic APIs Look to Strong 2016almost 11 years ago
Sun Pharmaceutical Issued Warning Letter for Microbial Violationsalmost 11 years ago
Collaboration Seeks to Reduce Animal Testingalmost 11 years ago
GENEWIZ Acquires Beckman Coulter Gene Servicesalmost 11 years ago
Recipharm Signs Agreement to Manufacture Liproca Depotalmost 11 years ago
Quotient Clinical Acquires Co-Formulate Limitedalmost 11 years ago
Capsugel to Acquire Xcelience and Powdersizealmost 11 years ago
FDA Warns of Potential Baclofen API Contaminationalmost 11 years ago
Althea Expands Biological Drug Product Manufacturing OperationsAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Germany’s Medical Biotechnology Sector is Flourishing
5